Xiaoyi Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyi Ren has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Fangyu Zhou
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
2 shared publications - Jiamin Ma
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
2 shared publications - Mengjie Yang
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
2 shared publications - Wenzhong Ji
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
2 shared publications Ningning Ren
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
1 shared publication- Ningning Ren
Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
1 shared publication
Latest Publications
- Open Access
- 21 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (34) , e50317
Associations between sex steroid hormones and female malignancies
Sex steroid hormones, including estradiol (E2), estrone (E1), follicle-stimulating hormone (FSH), and luteinizing hormone (LH), have been implicated in the development of female malignancies (FMs), yet their independent and combined effects remain unclear. We conducted a cross-sectional analysis using data from the National Health and Nutrition Examination Survey (NHANES). Weighted logistic regression, restricted cubic spline modeling, and chi-square trend tests were applied to evaluate dose-response associations. Machine learning algorithms, including Bayesian Kernel Machine Regression, Extreme Gradient Boosting, Shapley Additive Explanations, Least Absolute Shrinkage and Selection Operator regression, and Random Forest, were used to explore nonlinear relationships and assess variable importance in an exploratory manner. Sensitivity analyses confirmed the robustness of the findings. A total of 2108 participants were included. Higher FSH and LH levels were associated with increased odds of FMs, whereas higher E2 levels were associated with lower odds. In exploratory machine learning analyses, FSH and E1 were consistently ranked as important predictors of FMs. In this cross-sectional analysis, LH and FSH were associated with increased odds of FM, while higher E2 levels were inversely associated with malignancy risk. Exploratory machine learning analyses highlighted additional nonlinear patterns involving E2 and E1.
- 21 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (34) , e50317
Open AccessAssociations between sex steroid hormones and female malignancies
Sex steroid hormones, including estradiol (E2), estrone (E1), follicle-stimulating hormone (FSH), and luteinizing hormone (LH), have been implicated in the development of female malignancies (FMs), yet their independent and combined effects remain unclear. We conducted a cross-sectional analysis using data from the National Health and Nutrition Examination Survey (NHANES). Weighted logistic regression, restricted cubic spline modeling, and chi-square trend tests were applied to evaluate dose-response associations. Machine learning algorithms, including Bayesian Kernel Machine Regression, Extreme Gradient Boosting, Shapley Additive Explanations, Least Absolute Shrinkage and Selection Operator regression, and Random Forest, were used to explore nonlinear relationships and assess variable importance in an exploratory manner. Sensitivity analyses confirmed the robustness of the findings. A total of 2108 participants were included. Higher FSH and LH levels were associated with increased odds of FMs, whereas higher E2 levels were associated with lower odds. In exploratory machine learning analyses, FSH and E1 were consistently ranked as important predictors of FMs. In this cross-sectional analysis, LH and FSH were associated with increased odds of FM, while higher E2 levels were inversely associated with malignancy risk. Exploratory machine learning analyses highlighted additional nonlinear patterns involving E2 and E1.
- Open Access
- 2 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (1) , e46929
Comparative analysis of adverse events associated with epirubicin and doxorubicin: An observational study based on FDA Adverse Event Reporting System (FAERS) following STROBE guidelines
Breast cancer has overtaken lung cancer as the leading malignant tumor affecting women in many countries. Chemotherapy is one of the key adjuvant treatments for breast cancer. Epirubicin and Doxorubicin are the cornerstone of chemotherapy regimens used in clinical practice. This research utilized data extracted from the Food and Drug Administration Adverse Event Reporting System covering the period from the first quarter of 2004 to the third quarter of 2024. We confirmed the findings using the Bayesian confidence propagation neural network. From 2004 Q1 to 2024 Q3, Food and Drug Administration Adverse Event Reporting System contained 12,418,989 adverse event reports, with 5732 linked to Epirubicin and 30,613 to Doxorubicin. Febrile neutropenia (Epirubicin: 95% CI lower bound = 10.03, IC-2SD = 3.23; Doxorubicin: 95% CI lower bound = 32.68, IC-2SD = 4.89), cardiotoxicity (Epirubicin: 95% CI lower bound = 22.41, IC-2SD = 3.99; Doxorubicin: 95% CI lower bound = 62.02, IC-2SD = 5.68) exhibited a strong association with both Epirubicin and Doxorubicin. Epirubicin was more prone to the following adverse reactions: granulocyte count decreased (Epirubicin: χ 2 = 1092.8, 95% CI lower bound = 34.48, IC-2SD = 3.4). Doxorubicin was more prone to the following adverse reactions: hepatitis b reactivation (Doxorubicin: χ 2 = 7899.99, 95% CI lower bound = 39.17, IC-2SD = 4.91). Epirubicin was mainly associated with hematological, cardiac, and hepatobiliary adverse events, while Doxorubicin showed a broader spectrum, including neoplastic disorders and infections. Based on the above differences, the clinical drug selection should be balanced by the patient’s hematological status, cardiac function and HBV carrier/infection risk.
- 2 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (1) , e46929
Open AccessComparative analysis of adverse events associated with epirubicin and doxorubicin: An observational study based on FDA Adverse Event Reporting System (FAERS) following STROBE guidelines
Breast cancer has overtaken lung cancer as the leading malignant tumor affecting women in many countries. Chemotherapy is one of the key adjuvant treatments for breast cancer. Epirubicin and Doxorubicin are the cornerstone of chemotherapy regimens used in clinical practice. This research utilized data extracted from the Food and Drug Administration Adverse Event Reporting System covering the period from the first quarter of 2004 to the third quarter of 2024. We confirmed the findings using the Bayesian confidence propagation neural network. From 2004 Q1 to 2024 Q3, Food and Drug Administration Adverse Event Reporting System contained 12,418,989 adverse event reports, with 5732 linked to Epirubicin and 30,613 to Doxorubicin. Febrile neutropenia (Epirubicin: 95% CI lower bound = 10.03, IC-2SD = 3.23; Doxorubicin: 95% CI lower bound = 32.68, IC-2SD = 4.89), cardiotoxicity (Epirubicin: 95% CI lower bound = 22.41, IC-2SD = 3.99; Doxorubicin: 95% CI lower bound = 62.02, IC-2SD = 5.68) exhibited a strong association with both Epirubicin and Doxorubicin. Epirubicin was more prone to the following adverse reactions: granulocyte count decreased (Epirubicin: χ 2 = 1092.8, 95% CI lower bound = 34.48, IC-2SD = 3.4). Doxorubicin was more prone to the following adverse reactions: hepatitis b reactivation (Doxorubicin: χ 2 = 7899.99, 95% CI lower bound = 39.17, IC-2SD = 4.91). Epirubicin was mainly associated with hematological, cardiac, and hepatobiliary adverse events, while Doxorubicin showed a broader spectrum, including neoplastic disorders and infections. Based on the above differences, the clinical drug selection should be balanced by the patient’s hematological status, cardiac function and HBV carrier/infection risk.